Background: Bladder cancer (BC) remains a significant global health concern, and its incidence is influenced by a wide array of factors, including geography, sex, and socioeconomic status.
Objective: This systematic review evaluated the potential association between pioglitazone use and the risk of BC. We sought to determine whether pioglitazone, used in diabetes management, is associated with an increased risk of BC by reviewing recent studies.
Methods: A comprehensive search was conducted in the PubMed, Scopus, and Web of Science databases for relevant studies published between January 31, 2018 and July 31, 2024. From an initial pool of 212 articles, 176 were excluded due to failure to meet the inclusion criteria, 24 were removed for inadequate data or unclear conclusions, and six were eliminated due to inaccessibility. Ultimately, six eligible studies were included in the final review.
Results: Of the included studies, two suggested a potential association between pioglitazone use and an increased risk of BC, whereas four reported no statistically significant correlation.
Conclusion: These mixed findings highlight the need for further research that accounts for confounding factors, such as treatment duration and patient demographics. This systematic review emphasizes the importance of cautious interpretation regarding the safety profile of pioglitazone in relation to BC risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11810689 | PMC |
| http://dx.doi.org/10.14440/bladder.2024.0039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacologic and endotoxic reprogramming of renal vasodilatory, inflammatory, and apoptotic blemishes in weaning preeclamptic rats.
Sci Rep
March 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alazarita 21521, Alexandria, Egypt.
Preeclampsia (PE) and peripartum sepsis are two complications of pregnancy and are often associated with disturbed renal function due possibly to dysregulated renin angiotensin system. Here we evaluated hemodynamic and renal consequences of separate and combined PE and sepsis insults in weaning mothers and tested whether this interaction is influenced by prenatally-administered losartan (AT1-receptor blocker) or pioglitazone (PPARγ agonist). The PE-rises in blood pressure and proteinuria induced by gestational nitric oxide synthase inhibition (L-NAME, 50 mg/kg/day for 7 days) were attenuated after simultaneous treatment with losartan or pioglitazone.
View Article and Find Full Text PDFComparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis.
J Diabetes Complications
March 2025
Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali University, Dali 671000, Yunnan Province, China; National-Local Joint Engineering Research Center of Entomoceutics, Dali University, Dali 671000, Yunnan Province, China; College of Pharmacy Dali University, Dali 671000, Yunnan Province, China. Electronic address:
Objective: To comprehensively evaluate the therapeutic efficacy of pioglitazone and SGLT2 inhibitors (SGLT2i) in patients with MASLD and Type 2 Diabetes(T2DM).
Methods: Electronic databases, including Web of Science, PubMed, the Cochrane Library, China National Knowledge Internet (CNKI), Wan-Fang Digital Database, and China Science and Technology Journal Database (VIP) were searched from inception to December 2024. Two reviewers independently assessed study eligibility, performed continuous data extraction， and independently evaluated bias risks.
Enhanced transdermal delivery of pioglitazone hydrochloride via conductive hydrogel microneedles combined with iontophoresis.
Int J Pharm X
June 2025
Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Institute of Materia Medica, Hangzhou Medical College, Hangzhou 310013, China.
The conventional oral administration of pioglitazone for Type II diabetes management is frequently compromised by hepatic first-pass metabolism and associated systemic adverse effects, necessitating the development of enhanced transdermal delivery approaches. This study developed a transdermal drug delivery system combining conductive hydrogel microneedles and iontophoresis to improve the transdermal delivery of pioglitazone hydrochloride (PIO) and its therapeutic efficacy in the treatment of type II diabetes. The microneedles, fabricated using poly(methyl vinyl ether--maleic anhydride) as the main matrix material, exhibited excellent conductivity, mechanical strength, and high drug loading capacity.
View Article and Find Full Text PDFComparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.
J Prev Alzheimers Dis
February 2025
National Clinical Research Center for Metabolic Diseases, Key Laboratory of Cardiometabolic Medicine of Hunan Province, Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, PR China. Electronic address:
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options. Emerging evidence suggests that antidiabetic agents may offer neuroprotective effects by targeting shared pathophysiological mechanisms such as insulin resistance and neuroinflammation. However, the comparative efficacy, and safety of these agents in the treatment of AD remain unclear.
View Article and Find Full Text PDFNovel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation.
Eur J Med Chem
February 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. Electronic address:
A hybrid pharmacophore model, based on structural motifs previously identified by our team, was employed to generate ligands that simultaneously target COX-2, 15-LOX, and PPARγ in the context of metabolic dysfunction-associated fatty liver disease (MAFLD). Notable COX-2 inhibitory activities (IC = 0.065-0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!